InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
InspireMD announced that CEO Marvin Slosman will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
InspireMD announced that CEO Marvin Slosman will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. The presentation is scheduled for June 9 at 11:30 AM ET on Track 3. Investors can register to watch the presentation here. The company aims to set its MicroNet® technology as the standard for carotid stenting, enhancing stroke-free outcomes. InspireMD's common stock trades on Nasdaq under the symbol NSPR.
Details
News Market Reaction – NSPR
The recorded move for NSPR in the trading session of this news was -0.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.
Mr. Slosman will deliver his corporate presentation on June 9 at 11:30am ET, Track 3.
Investors can register to watch the presentation here.
Investors interested in scheduling a meeting with management should contact assistant@ldmicro.com.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
InspireMD’s common stock is quoted on the Nasdaq-CM under the ticker symbol NSPR. The Company’s warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (“Nasdaq”). Trading is expected to begin on June 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
CORE IR
investor-relations@inspiremd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.